MD Anderson Cancer Center
Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients.
Neon Therapeutics is a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes.
We pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies. Our platform uses neoantigen targets to induce and expand each patient’s immune responses to recognize and kill cancer and comprises three key elements that form an iterative feedback loop: our RECON Bioinformatics Engine; our capabilities in peptide chemistry; and our combined T cell biology and immune-monitoring expertise.
Our company builds on more than a decade of pioneering work by our world-class scientific founders across multiple leading global institutions including the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, MD Anderson Cancer Center, the Netherlands Cancer Institute and Washington University in St. Louis. Our founders were central to the development of both the fields of immuno-oncology and neoantigens and have published a number of seminal papers outlining the importance of neoantigens as critical immune targets for treating cancer.
Headquartered in Cambridge, Mass., Neon Therapeutics launched in 2015. Neon raised $161 million in private financing from Third Rock Ventures, Fidelity Management & Research Company, Partner Fund Management, Wellington Management, Pharmstandard International, Arrowmark Partners, Nextech Invest, Hillhouse Capital Group, Casdin Capital, Clal Biotechnology Industries, Access Industries and others.
MD Anderson Cancer Center
Founder-in-Residence, Neon Therapeutics
Netherlands Cancer Institute
Dana-Farber Cancer Institute
Board of Directors
Chairman; Partner, Third Rock Ventures
Entrepreneur-In-Residence, Third Rock Ventures
Founding Director, Broad Institute
Chief Executive Officer, Neon Therapeutics
Clinical Professor of Medicine, University of California San Francisco
Partner, Third Rock Ventures
Chairman & CEO, Gamida Cell
Former Novartis executive
Director of Immunotherapy, Professor of Medicine, Division of Hematology & Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Professor of Medicine, Harvard Medical School; Director, the Henri and Belinda Termeer Center for Targeted Therapy, Director of Clinical Research, Massachusetts General Hospital
Head of Medical Oncology, Staff Scientist, Netherlands Cancer Institute; Professor, Leiden University Medical Centre
Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Yale School of Medicine
Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
Chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center